Compare Amylx Pharmaceuticals Inc (AMLX) vs British American Tobacco PLC (BTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs British American Tobacco PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while British American Tobacco PLC trades at $56.04 (market cap $122.36B). The key difference: British American Tobacco PLC is far larger — about 46.3× Amylx Pharmaceuticals Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BTI | |
|---|---|---|
Market Cap | $2.64B | $122.36B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $66.70 |
52-Week Low | $7.82 | $50.39 |
Enterprise Value | $2.39B | $166.31B |
Dividend Yield | — | 5.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
BTI trades at $55.93, down 1.96% today, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with an 83.56% gross margin and 24.99% net income margin, supported by a P/E of 14.48. Recent news highlights strategic tech partnerships and workforce restructuring to drive efficiency.
The outlook is cautious due to declining cash flow and regulatory risks, but the 5%+ dividend yield and analyst buy consensus (66.7%) offer value. Upside depends on successful transition to next-generation products, while core combustible declines and debt levels pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
